☆ 4.6 Article

Donafenib: First Approval

DRUGS (2021)

Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial

Yan-Song Lin et al.

Summary: The study evaluated the efficacy and safety of the new multikinase inhibitor donafenib in treating locally advanced or metastatic RAIR-DTC. Both 200mg and 300mg doses of donafenib showed similar efficacy in terms of objective response rate, with the 300mg dose demonstrating a trend towards longer progression-free survival and more tumor shrinkage. The most common grade 3 treatment-related adverse events were palmar-plantar erythrodysesthesia and hypertension.

THYROID (2021)

添加到收藏夹

Article Oncology

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin et al.

Summary: This study demonstrated that donafenib is more effective than sorafenib in treating advanced hepatocellular carcinoma, showing promise in improving patients' survival outcomes, and exhibiting favorable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours

Xiaoyu Li et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities

Lili Zhong et al.

MOLECULAR DIVERSITY (2019)

添加到收藏夹

Review Oncology

Clinical development of targeted and immune based anti-cancer therapies

N. A. Seebacher et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Meeting Abstract Oncology

A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.

Feng Bi et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Donafenib: First Approval

相关参考文献

Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours

Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial

Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities

Clinical development of targeted and immune based anti-cancer therapies

A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.

导出引文

分享论文